Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA3 | P07451 | 3/20 | 0.37 |
| ▸ | CA4 | P22748 | 3/20 | 0.37 |
| ▸ | CA6 | P23280 | 3/20 | 0.37 |
| ▸ | CA5A | P35218 | 3/20 | 0.37 |
| ▸ | CA7 | P43166 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13703903 | 1.00 | CHRM2 (0.72) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL11587714 | 0.97 | CHRM2 (0.77) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL15594 | 0.97 | CHRM2 (0.77) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL4805968 | 0.93 | CHRM2 (0.72) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL8736488 | 0.93 | CHRM2 (0.82) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL25443482 | 0.93 | CHRM2 (0.72) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL12946143 | 0.91 | CHRM2 (0.62) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL2979957 | 0.91 | CHRM2 (0.62) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| SCHEMBL12946136 | 0.91 | CHRM2 (0.62) | CHRM2TDP1CYP2C9CYP2C19NFKB1 | |
| Hydroxyamine SCHEMBL8417352 | 0.90 | CHRM2 (0.68) | CHRM2TDP1CYP2C9CYP2C19NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117801262-A | Leveling agent, electroplating composition and application thereof | 华为技术有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024061290-A1 | LEVELING AGENT, ELECTROPLATING COMPOSITION, AND USE THEREOF | 华为技术有限公司 | 2024-03-28 | — | — | WO | disclosed |
| US-8148577-B2 | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110092601-A1 | LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110039266-A1 | FLOWCELL SYSTEMS FOR SINGLE MOLECULE DETECTION | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | JOHN HOPKINS UNIVERSITY (US) | 2007-09-06 | — | — | US | disclosed |
| US-4647409-A | Copper-phthalocyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1987-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208082-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | CHRM2 3888/4885TDP1 258/4885CYP2C9 4143/4885 |
| US-20100273745-A1 | POLYAMINES USEFUL AS ANTI-PARASITIC AND ANTI-CANCER THERAPEUTICS AND AS LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM1A, JMJD6, SRM | CHRM2 3888/4885TDP1 258/4885CYP2C9 4143/4885 |
| US-20110092601-A1 | LYSINE-SPECIFIC DEMETHYLASE INHIBITORS | KDM4E, KDM3A, KDM2A | CHRM2 3908/4885TDP1 158/4885CYP2C9 3448/4885 |
| US-20110039266-A1 | FLOWCELL SYSTEMS FOR SINGLE MOLECULE DETECTION | POLN, POLQ, POLL | CHRM2 3675/4885TDP1 1380/4885CYP2C9 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.